|
Table 1: Baseline, follow-up characteristics and NNRTI regimen modifications among the 769 patients initiating ART at the Mbabane Government Hospital ART Unit |
||||
|
Characteristics |
NVP- based, n (%) |
EFV- based, n (%) |
p-value |
|
|
Total |
578 (75.2%) |
191 (24.8%) |
|
|
|
Gender |
|
|
|
|
|
Female, n (%) |
417 (72.2%) |
95 (49.7%) |
<0.001* |
|
|
Male, n (%) |
161 (27.9%) |
96 (50.3%) |
|
|
|
|
|
|
|
|
|
WHO stage |
|
|
|
|
|
II/II, n (%) |
259 (47.8%) |
80 (44.9%) |
|
|
|
III/IV, n (%) |
283 (52.2%) |
98 (55.1%) |
0.5* |
|
|
CD4 count, median (IQR) |
119 (67 - 187) |
102 (56 - 171) |
0.06¶ |
|
|
Weight , median (IQR) |
62 (55 - 69.5) |
60 (55 - 68) |
0.67¶ |
|
|
Age, median (IQR) |
35.3 (30.7 - 42.9) |
36.9 (32.1 - 43.2) |
0.19¶ |
|
|
|
|
|
|
|
|
Regimen |
|
|
|
|
|
d4T/3TC backbone, n (%) |
282 (48.8%) |
38 (19.9%) |
<0.001* |
|
|
AZT/3TC backbone, n (%) |
296 (51.2%) |
153 (80.1%) |
|
|
|
LTFU, n (%) |
90 (15.6%) |
42 (22%) |
0.04* |
|
|
Poor regimen tolerability to either NVP or EFV, n (%) |
26 (4.5%) |
4 (2.1%) |
0.16* |
|
|
|
||||
|
Reasons for poor regimen durability |
||||
|
|
||||
|
Contraindication |
|
|
|
|
|
TB treatment |
14 |
0 |
|
|
|
Drug shortage |
2 |
0 |
|
|
|
|
|
|
|
|
|
Toxicity |
|
|
|
|
|
Raised AST/ALT/hepatitis |
4 |
0 |
|
|
|
CNS disturbances |
0 |
3 |
|
|
|
Gynaecomastia |
0 |
1 |
|
|
|
Lactic acidosis |
1 |
0 |
|
|
|
Rash or hypersensitivity |
4 |
0 |
|
|
|
Treatment failure** |
1 |
0 |
|
|
|
Total modifications |
26 |
4 |
|
|
|
NNRTI, non-nucleoside reverse transcriptase inhibitor; NVP-Nevirapine; EFV-Efavirenz; d4T-stavudine; AZT-zidovudine; 3TC-lamuvidine; LTFU-Loss to follow-up; TB-tuberculosis; AST- Aspartate transferase; ALT- Alanine transferase; CNS- Central Nervous System. * Pearson’s Chi-square test used. ¶Wilcoxon Rank-sum test used. **viral loads were not done routinely but only for patients with clinical suspicion of treatment failure after at least 6 months on treatment. |
||||